Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Silva, L. (Leyre) | - |
dc.creator | Egea, J. (Josune) | - |
dc.creator | Villanueva, L. (Lorea) | - |
dc.creator | Ruiz, M. (Marta) | - |
dc.creator | Llopiz, D. (Diana) | - |
dc.creator | Repáraz-Pernaut, D. (David) | - |
dc.creator | Aparicio-De-la-Torre, B. (Belén) | - |
dc.creator | Lasarte-Cia, A. (Aritz) | - |
dc.creator | Lasarte, J.J. (Juan José) | - |
dc.creator | Ruiz-de-Galarreta-Martínez, M. (Marina) | - |
dc.creator | Lujambio, A. (Amaya) | - |
dc.creator | Sangro, B. (Bruno) | - |
dc.creator | Sarobe, P. (Pablo) | - |
dc.date.accessioned | 2023-03-23T08:51:21Z | - |
dc.date.available | 2023-03-23T08:51:21Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Silva, L. (Leyre); Egea, J. (Josune); Villanueva, L. (Lorea); et al. "Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma". Cancers. 12 (11), 2020, | es |
dc.identifier.uri | https://hdl.handle.net/10171/65770 | - |
dc.description.abstract | Therapies based on immune checkpoint inhibitors (ICPI) have yielded promising albeit limited results in patients with hepatocellular carcinoma (HCC). Vaccines have been proposed as combination partners to enhance response rates to ICPI. Thus, we analyzed the combined effect of a vaccine based on the TLR4 ligand cold-inducible RNA binding protein (CIRP) plus ICPI. Mice were immunized with vaccines containing ovalbumin linked to CIRP (OVA-CIRP), with or without ICPI, and antigen-specific responses and therapeutic efficacy were tested in subcutaneous and orthotopic mouse models of liver cancer. OVA-CIRP elicited polyepitopic T-cell responses, which were further enhanced when combined with ICPI (anti-PD-1 and anti-CTLA-4). Combination of OVA-CIRP with ICPI enhanced ICPI-induced therapeutic responses when tested in subcutaneous and intrahepatic B16-OVA tumors, as well as in the orthotopic PM299L HCC model. This effect was associated with higher OVA-specific T-cell responses in the periphery, although many tumor-infiltrating lymphocytes still displayed an exhausted phenotype. Finally, a new vaccine containing human glypican-3 linked to CIRP (GPC3-CIRP) induced clear responses in humanized HLA-A2.01 transgenic mice, which increased upon combination with ICPI. Therefore, CIRP-based vaccines may generate anti-tumor immunity to enhance ICPI efficacy in HCC, although blockade of additional checkpoint molecules and immunosuppressive targets should be also considered. | es_ES |
dc.description.sponsorship | This research was funded by grants from Caixaimpulse Program (CI17-00064), Instituto de Salud Carlos III co-financed by European FEDER funds (PI17/00249), Fundación Bancaria La Caixa “Hepacare” project, Gobierno de Navarra “AGATA” project and “Murchante contra el Cáncer” initiative to P. Sarobe. J.J.Lasarte is funded by Ministerio de Ciencia e Innovación (PID2019-108989RB-I00). B. Sangro is funded by Instituto de Salud Carlos III /EU TRANSCAN-2 (AC16/00065) and Instituto de Salud Carlos III co-financed by European FEDER funds (PI19/00742). M. Ruiz de Galarreta was supported by the Fundación Alfonso Martín Escudero Fellowship and the Damon Runyon-Rachleff Innovation Award (DR52-18). A. Lujambio was supported by a Damon Runyon-Rachleff Innovation Award (DR52-18), R37 Merit Award (R37CA230636), DoD Career Development Award (CA150178), DoD Translational Team Science Award (CA150272P2), and the Icahn School of Medicine at Mount Sinai. | es_ES |
dc.language.iso | eng | es_ES |
dc.relation | info:repo-eu/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI17%2F00249/ES/VACUNACION TERAPEUTICA PARA POTENCIAR LA INMUNOTERAPIA FRENTE AL HEPATOCARCINOMA | es_ES |
dc.relation | info:repo-eu/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2019-108989RB-I00/ES/EL MICROAMBIENTE TUMORAL COMO DIANA PARA EL DESARROLLO DE INMUNOTERAPIAS CAR-T EN TUMORES SOLIDOS | es_ES |
dc.relation | info:repo-eu/grantAgreement/MINECO/Acciones Complementarias de programación conjunta internacional (AE Salud 2016)/AC16%2F00065/ES/Mutated neo-antigens in hepatocellular carcinoma | es_ES |
dc.relation | info:repo-eu/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI19%2F00742/ES/INHIBICION DE GENES NO CODIFICANTES CON VALOR TERAPEUTICO EN HEPATOCARCINOMA. ANALISIS DE MONOTERAPIAS Y TERAPIAS COMBINADAS | es_ES |
dc.relation | info:eu-repo/grantAgreement/NIH/NATIONAL_CANCER_INSTITUTE/1R37CA230636-01/US | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Cold-inducible RNA binding protein | es_ES |
dc.subject | Therapeutic vaccination | es_ES |
dc.subject | Hepatocellular carcinoma | es_ES |
dc.subject | Immune checkpoint inhibitors | es_ES |
dc.title | Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.identifier.doi | 10.3390/cancers12113397 | - |
dadun.citation.number | 11 | es_ES |
dadun.citation.publicationName | Cancers | es_ES |
dadun.citation.volume | 12 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.